Select Publications

Gennari A et al. Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. Breast Cancer Res Treat 2008;[Epub ahead of print]. Abstract

Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol2008;21(Suppl 2):8-15. Abstract

Paik S et al. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358(13):1409-11. No abstract available

Pegram M et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 301.

Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131(1):18. Abstract

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS
Nancy E Davidson, MD
- Select publications

Professor John Crown, MD
- Select publications

Kathy D Miller, MD
- Select publications

Peter M Ravdin, MD, PhD
- Select publications

THREE PERSPECTIVES ON US COOPERATIVE GROUP RESEARCH

Norman Wolmark, MD
- Select publications

Joyce O’Shaughnessy, MD
- Select publications

Eric P Winer, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office